Nueva dosificación de un bifosfonato para la prevención y el tratamiento de la osteoporosis posmenopáusica

In postmenopausal therapy of osteoporosis, the patient must become aware of the need for treatment adherence indicated by his/her doctor. In the specific case of bisphosphonates, it has been seen that after one year, the patient stops taking the medication regardless of whether this is daily or weekly. That is why a once-monthly dose may increase therapeutic compliance. Those doctors interested in the subject can use Ibandronate, a potent nitrogen-containing bisphosphonate that has been approved for use with 150 mg as a once-monthly regimen, with proven efficacy and tolerability in type A1 multicenter studies because it increases bone mineral density (both in the hip and the lumbar spinal), produces significant decrease from the baseline of the biochemical markers of bone turnover as it decrease serum and urinary C-telopeptide of the α-chain of type 1 collagen (CTX) and reduces new vertebral fracture risk. The majority of patients preferred once-monthly ibandronate.